HROW Stock News & Analysis | Latest Updates

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relations and Communications, succeeding Jamie Webb, Director of Communications and Investor Relations, who recently announced her retirement. Jamie will remain in her role into August to support a smooth and effective transition. “We are excited to welcome Mike to the Harrow Family. His wealth of exper

June 18, 2025Appointments

HROW News

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

William Blair Bullish On Harrow's High-Margin Branded Eye Drug Strategy

Assessing Harrow: Insights From 4 Financial Analysts

Harrow Secures Exclusive US Commercial Rights To BYQLOVI, The First Ophthalmic Steroid Of Its Class Approved In Over 15 Years

Where Harrow Stands With Analysts

HC Wainwright & Co. Maintains Buy on Harrow, Raises Price Target to $60

Harrow FY2025 Revenue Outlook Of $280.00M+ Vs $283.19M Est

Harrow Q1 Adj. EPS $(0.38) Misses $(0.05) Estimate, Sales $47.83M Miss $57.00M Estimate

Examining the Future: Harrow's Earnings Outlook

Nordic Pharma Partners With Harrow To Launch Authorized Generic Of Maxitrol To Treat Bacterial Eye Infections

Harrow Offers FDA-Approved Dry Eye Treatment for $59 as Klarity-C Patients Transition to VEVYE

Where Harrow Stands With Analysts

B. Riley Securities Maintains Buy on Harrow, Lowers Price Target to $65

HC Wainwright & Co. Reiterates Buy on Harrow, Maintains $57 Price Target

Harrow Q4 2024 Adj. EPS $0.40 Beats $0.07 Estimate, Sales $66.800M Beat $61.790M Estimate

Harrow Announces Centers for Medicare & Medicaid Service Approved Co.'s Transitional Pass-Through Application For TRIESENCE

Reported March 17, 2025: Harrow Sees Q4 2024 Revenue $65M-$67M Vs $58.41M Est.; FY24 Revenue $198M-$200M Vs $191.18M Est.

HC Wainwright & Co. Reiterates Buy on Harrow, Maintains $57 Price Target

Harrow Unveils VEVYE Access For All Initiative

Harrow Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Harrow Executed A Five-year Strategic Supply And Development Agreement For FDA-approved Triesence, A Preservative-free Synthetic Corticosteroid For Visualization During Vitrectomy And The Treatment Of Ocular Inflammatory Conditions That Are Unresponsive T

Melt Pharmaceuticals Announced Positive Topline Results Of Its Pivotal Phase 3 Study Evaluating The Safety And Efficacy Of Its Lead Product Candidate, Melt‑300, A Non-iv, Non-opioid Tablet For Procedural Sedation During Cataract Surge

Melt Pharmaceuticals Announces MELT-210 Top-Line Results Of Phase 1 Pharmacokinetics Study For Procedural Sedation; Co. Reports 'Bioavailability of MELT-210 Compares Favorably to Reference Drug'